The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Open accessAbstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, because, while seemingly infrequent, it is often fulminant and lethal. The underlying basis of ICI-associated myocarditis is not completely understood. While the importance of T cells is clear, the inciting antigens, why they are recognized, and the mechanisms leading to cardiac cell injury remain poorly characterized. These issues underscore the need for basic and clinical studies to define pathogenesis, identify predictive biomarkers, improve diagnostic strategies, and develop effective treatments. An improved understanding of ICI-associated myocarditis will provide insights into the equilibrium between the immune and cardiovascular systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This discovery suggests a potential involvement of autoreactive T cells targeting α -MyHC in the initiation and progression of other forms of myocarditis.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent cases of ICI myocarditis have expanded our insights into the role of α -MyHC-specific T cells in myocarditis development. 41-46”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ICI myocarditis emerges as an infrequent but potentially fatal condition associated with ICI therapies, especially when used in combination”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“PD-1 and PD-L1 blockers mediated similar responses in patients with advanced and otherwise untreatable melanoma, non–small cell lung carcinoma, and urothelial tumors (77, 78).”
BackgroundCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–240 of 240
Zhang, X.-T., Ge, N., Xiang, Z.-J., & Liu, T. (2022) · Figshare · doi:10.6084/m9.figshare.21592463
Zhong, J., & Shi, Y. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.141022
Quagliariello, V., Passariello, M., Belardo, M., Esposito, A., Paone, M., Berretta, M., Iovine, M., Barbato, M., Canale, M. L., Paccone, A., et al. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001798
Quinaglia, T., Coelho‐Filho, O. R., & Sposito, A. S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1823320
Cardio-oncology, from Guidelines to Practice: Filling the Gap – an Eastern European Viewpoint
Ivănescu, A. C., Dulf, P. L., Dulf, D. V., & Dan, G. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.102
Dangerous Side-effects of New Treatments
Ludeña, R., Ptaszynski, R., Nieves, B., Fernández, M., & Gutierrez, L. (2026) · European Cardiology Review · doi:10.15420/ecr.2026.21.s1.po33
Multimodality Imaging in Myocarditis: Integrating Etiology, Diagnosis, and Risk Stratification
Cheikh-Debs, D., Rushworth, P., Liu, J., Lee, C., Moslehi, J. J., & Salerno, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02374-4
Self-citationPătru, I.-R., Atasiei, D.-I., Ionescu, R. T., Negru, A. G., Antone-Iordache, I.-L., Iordache, M., Anghel, A.-V., & Ionescu, A. O. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104378
Mouse models of immune-related adverse events: progress, challenges, and opportunities
Παπαδόπουλος, Θ., Pinto, A., Abraham, M. J., Naranjo, C. L., Molina, M. F., Hudson, M., Miller, W. H., & Rincon, S. V. D. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.010
Wang, X., Cai, M., Zhou, Y., Feng, M., Chen, P., Zhang, J. I.-X., Liu, S., Song, Y., Zhu, C., Chen, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.726115
Zhou, Y., Zhang, Z., Liu, S., Nan, J., Zhang, Z., & Chen, Z. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1749534
Fang, H., Guo, B., Sun, Y., Jin, W., & Wang, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1845366
Du, J., Han, S., Song, R., Wang, J., Zhang, L., Xu, Y., Zhou, H., Wang, F., Qin, S., Xu, D., et al. (2026) · Nature Nanotechnology · doi:10.1038/s41565-026-02196-z
Andonotopo, W., Bachnas, M. A., Pramono, M. B. A., Dewantiningrum, J., Gumilar, K. E., Darmawan, E., Akbar, M. I. A., Aldiansyah, D., Yeni, C. M., Nugraha, L. A. K., et al. (2026) · JAP Academy Journal · doi:10.4103/japaj.japaj_2_26
Liu, T., Meng, X., Li, Y., Mi, F., Yang, X., & Sha, S. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2694884
Fan, Z., Mei, Y., Liu, K., Zhang, Y., & Shi, L. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156613
Ye, C., Jiang, Z.-T., Yan, C., Li, X., Zhu, Y.-H., Zeng, L.-Y., & Luo, L. (2026) · Human Cell · doi:10.1007/s13577-026-01415-y
Cabillon, A., Camejo, N., Amarillo, D., García, F., Suaya, V., Castillo, C., & Krygier, G. (2026) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2026.4(4).10
Zhang, B., Liu, G., Zhou, K., Zhang, X., Fan, Y., Xu, Y., & Wei, W. W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1870541
Chen, N. K., Hok, K. D., Chokshi, N., Shadid, A., Rich, H. E., Gunamalai, L., Doursout, M., Banda, N. K., & Shivshankar, P. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1872588
Chen, C., Shi, J., Lei, Y., Wang, Q., Cao, P., Hou, D., Huang, M., Wang, R., Mu, Q., Lv, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76158-3
Li, J., Zhao, Y., & Bai, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1903190
Wen, J., Yang, S. M., & Chen, C. (2026) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2026.44
Pang, J., Zhu, W., Zhang, Y., & Guo, W. (2026) · Journal of International Medical Research · doi:10.1177/03000605261475733
Clinical Syndromes of Peripheral Nervous System Neurotoxicity from Immune-Checkpoint Inhibitors
Smith, I., Choi, M., & Sabadia, S. B. (2026) · Seminars in Neurology · doi:10.1055/a-2936-5945
Kalluri, U., & Subair, M. N. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1665
Cardiac toxicity of adjuvant breast cancer radiotherapy in the targeted therapy era
Kolářová, I., Melichar, B., Sirák, I., Vaňásek, J., Hlávka, A., Horáčková, K., Pohanková, D., & Vošmik, M. (2026) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.114490
Ahmed, Y., Ibrahim, H., Sabu, D., Ismail, H., & Farooq, F. (2026) · Discover Medicine · doi:10.1007/s44337-026-00696-4
Che, L., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896304
Zhou, Y., Wu, Y., Zhang, N., Wang, S., Ye, X., Ma, J., Li, Q., & Wang, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.14.751375
Cai, R., Shen, S., & Gu, C. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1917892
Lin, X., Yao, X., & Li, J. (2026) · Cells · doi:10.3390/cells15191734
Ammirati, E., Guglielmo, G., Veronese, G., ADLER, E. D., Mäyränpää, M. I., Bonoldi, E., Petrella, D., Kim, P. J., Brambatti, M., Vaira, M. P., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103254
Self-citationCardiac Troponin at Discharge and Mortality After Acute MyocarditisPreprint
Kaplan, A., Engelstein, H., Faierstein, K., Prinz, E., Copeland, V., Segev, A., Younis, A., Mansour, M. A., Al-Rub, T. A., Matetzky, S., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7582995
Heart-specific T cell responses: from antigens to disease mechanisms
Ramos, G. C. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01356-x
Zeng, L., You, K., Kang, B., Xiao, L., Lin, G., Wang, Y., Huang, A., & Zhou, X. (2026) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2026.142093
Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis
Leng, J., Wang, C., & Bai, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857298
Wang, S., Ding, Q., Ding, S., Chunli, L., & Li, Q. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.053190
Dong, L., Zhang, L., Song, L., Qu, C., Wang, X., Xiao, S., Tian, M., Wang, P., Zhi, H., Zhao, Y., et al. (2026) · iScience · doi:10.1016/j.isci.2026.118063
Immune checkpoint inhibitor–associated orbital inflammation: a systematic review
Paris, J. E., La, E., Agarwal, A., Tong, J. Y., Slattery, J. A., Chan, W. O., & Selva, D. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07589-3
Metadata
- Authors
- Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N.
- Affiliations
- Vanderbilt University Medical Center (US)
- Brigham and Women's Hospital (US)
- Université Paris Cité (FR)
- Albert Einstein College of Medicine (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2021-03-01
- Volume
- 131
- Issue
- 5
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7919710
- OpenAlex
- W3134997217
- Cited by
- 237
- References
- 181
- Citations by year
- 2026: 60 · 2025: 46 · 2024: 46 · 2023: 32 · 2022: 40 · 2021: 13
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (PR191593)
- American Heart Association (18SRG34280018)
- Vanderbilt University
- Vanderbilt University Medical Center
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL131862, R01HL130861, R01HL141466, R01HL138475)
- National Institute of Allergy and Infectious Diseases (P01AI056299, P01AI039671)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, T cell-mediated inflammation, predictive biomarkers, diagnostic approach, cancer immunotherapy toxicity
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Myocarditis, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
